NUVIGIL Launch Enhanced by Robust Patient Access Programs
FRAZER, Pa., June 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) today announced that NUVIGIL(R) (armodafinil) Tablets [C-IV], a
longer-lasting form of modafinil, is now available. NUVIGIL is
indicated to improve wakefulness throughout the day for the millions of
patients who struggle with excessive sleepiness associated with treated
obstructive sleep apnea, shift work sleep disorder, also known as shift work
disorder, and narcolepsy. Cephalon has finalized the commercialization plans
for NUVIGIL and, beginning today, any patient with a NUVIGIL prescription
should be able to obtain the medication from their pharmacy or have it filled
within 24 hours.
"We are proud to be able to bring NUVIGIL to physicians and patients and
to increase access to the medication through our patient support programs.
Physicians have told us that they want and need a longer-lasting medication
for their patients, and NUVIGIL delivers on that need," said Frank Baldino,
Jr., Ph.D., Chairman and CEO, Cephalon.
Expanded Access Programs
As part of the launch of NUVIGIL, Cephalon is introducing several new
programs designed to expand access for both patients and healthcare providers.
To assist insured patients with co-pay costs for NUVIGIL, Cephalon will offer
the NUVIGIL Prescription Savings Program. Through this program, eligible
patients will receive a co-pay savings at the pharmacy to reduce their
out-of-pocket costs to fill the prescription. To help patients and healthcare
providers navigate the authorization and reimbursement process, Cephalon
established the NUVIGIL Reimbursement Hotline. The company is also working
with managed care organizations in order to provide greater patient access for
NUVIGIL through health plans nationwide.
In addition, this year Cephalon created the CephalonCares(SM) Foundation.
CEO Frank Baldino, Jr., said, "We recognize that uninsured patients often
cannot afford the costs of medications, especially in these economic times.
Therefore, we created the CephalonCares Foundation to provide free medication
to eligible patients so that they can access our products when they are in
need." More information on the CephalonCares Foundation, eligibility
guidelines and the products included in the program can be found at
Clinical Development Plans
Cephalon is also exploring the potential for NUVIGIL to treat the symptoms
associated with an array of medical disorders. The company recently announced
results from a phase three clinical trial of NUVIGIL as a treatment for
patients with excessive sleepiness associated with jet lag disorder. Those
data are expected to be submitted as part of a supplemental New Drug
Application (sNDA) later this year.
In addition, the company has an extensive clinical development program in
place to further study the efficacy and safety of NUVIGIL in bipolar
depression, the negative symptoms of schizophrenia, cancer treatment-related
fatigue and excessive sleepiness associated with traumatic brain injury.
"We are encouraged by what we've seen to date from the clinical
development program for NUVIGIL. We believe that our continued research into
NUVIGIL will enable us to define the full range of benefits that this
medication will be able to provide for patients with a variety of medical
conditions," added Dr. Lesley Russell, Executive Vice President and Chief
Medical Officer at Cephalon.
NUVIGIL is indicated to improve wakefulness in patients with excessive
sleepiness associated with treated obstructive sleep apnea (OSA), shift work
sleep disorder, also known as shift work disorder (SWD) and narcolepsy. The
NUVIGIL label includes a bolded warning for serious or life-threatening rash,
including Stevens-Johnson Syndrome, that has been reported in adults and
children taking modafinil, a racemic mixture of S and R modafinil (the latter
is armodafinil, the active ingredient in NUVIGIL). NUVIGIL is not approved
for use in pediatric patients for any indication.
The most common adverse events in controlled clinical trials (greater than
5 percent) were headache, nausea, dizziness, and insomnia. Full prescribing
information for NUVIGIL is available at www.NUVIGIL.com.
About Cephalon, Inc.
Founded in 1987, Cephalon, Inc. is an international biopharmaceutical
company dedicated to the discovery, development and commercialization of many
unique products in four core therapeutic areas: central nervous system,
inflammatory diseases, pain and oncology. A member of the Fortune 1000 and the
S&P 500 Index, Cephalon currently employs approximately 3,000 people in the
United States and Europe. U.S. sites include the company's headquarters in
Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in
West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis,
Cephalon has a growing presence in Europe, the Middle East and Africa.
The Cephalon European headquarters and pre-clinical development center are
located in Maisons-Alfort, France, just outside of Paris. Key business units
are located in England, Ireland, France, Germany, Italy, Spain, the
Netherlands for the Benelux countries, and Poland for Eastern and Central
European countries. Cephalon Europe markets more than 30 products in four
areas: central nervous system, pain, primary care and oncology.
The company's proprietary products in the United States include: NUVIGIL,
TREANDA(R) (bendamustine hydrochloride) for Injection, AMRIX(R)
(cyclobenzaprine hydrochloride extended-release capsules), FENTORA(R)
(fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection,
GABITRIL(R) (tiagabine hydrochloride), PROVIGIL(R) (modafinil) Tablets [C-IV],
and ACTIQ(R) (oral transmucosal fentanyl citrate) (C-II). The company also
markets numerous products internationally. Full prescribing information on its
U.S. products is available at http://www.cephalon.com or by calling
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs, development of potential pharmaceutical
products, interpretation of clinical results, clinical development of NUVIGIL,
prospects for regulatory approval, manufacturing development and capabilities,
market prospects for its products, sales and earnings guidance, and other
statements regarding matters that are not historical facts. You may identify
some of these forward-looking statements by the use of words in the statements
such as "anticipate," "estimate," "expect," "project," "intend," "plan,"
"believe" or other words and terms of similar meaning. Cephalon's performance
and financial results could differ materially from those reflected in these
forward-looking statements due to general financial, economic, regulatory and
political conditions affecting the biotechnology and pharmaceutical industries
as well as more specific risks and uncertainties facing Cephalon such as those
set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S.
Securities and Exchange Commission. Given these risks and uncertainties, any
or all of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Cephalon does not intend to update publicly any
forward-looking statement, except as required by law. The Private Securities
Litigation Reform Act of 1995 permits this discussion.
SOURCE: Cephalon, Inc.
Web Site: http://www.cephalon.com